Crossmark

BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer

Crossref DOI link: https://doi.org/10.1186/s13058-018-0935-9

Published Online: 2018-01-24

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Weber-Lassalle, Nana

Hauke, Jan

Ramser, Juliane

Richters, Lisa

Groß, Eva

Blümcke, Britta

Gehrig, Andrea

Kahlert, Anne-Karin

Müller, Clemens R.

Hackmann, Karl

Honisch, Ellen

Weber-Lassalle, Konstantin

Niederacher, Dieter

Borde, Julika

Thiele, Holger

Ernst, Corinna

Altmüller, Janine

Neidhardt, Guido

Nürnberg, Peter

Klaschik, Kristina

Schroeder, Christopher

Platzer, Konrad

Volk, Alexander E.

Wang-Gohrke, Shan

Just, Walter

Auber, Bernd

Kubisch, Christian

Schmidt, Gunnar

Horvath, Judit

Wappenschmidt, Barbara

Engel, Christoph

Arnold, Norbert

Dworniczak, Bernd

Rhiem, Kerstin

Meindl, Alfons

Schmutzler, Rita K.

Hahnen, Eric
Funding

Funding for this research was provided by:

Deutsche Krebshilfe (109076, 70111850)

Ministry for Innovation, Science and Research of the State of North Rhine-Westphalia (323-8.0302.16.02-132142)
More Information

Article History

Received: 21 September 2017

Accepted: 10 January 2018

First Online: 24 January 2018

Ethical approval and consent to participate

: Written informed consent was obtained from all patients and control individuals, and ethical approval was granted by the Ethics Committee of the University of Cologne (07-048).

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.